Figure 5.

Combined with carboplatin, 2DG reduces tumor burden of PDX models of OCC. (A) Images of hematoxylin and eosin stained sections of representative tumors from patient LP121, PH138 and PH250, and PDX models developed from these tumors. Morphological features of patient tumors are retained in the corresponding PDX. (B) Graph of tumor nodules ≥8 mm³. For each model cell, slurry was injected i.p. into female NSG mice. After two weeks of growth, tumors were treated with PBS (control), 2DG (50 mg/kg twice weekly), carboplatin (1 mg/kg/week), or 2DG and carboplatin. Treatments continued until control mice reached ethical endpoint, when all mice were euthanized, and tumor burden quantified by counting tumor nodules ≥ 8 mm³. Results are presented as mean +/− SD. *, p ≤ 0.05; **, p ≤ 0.01.